PCSK9 inhibitors - mechanisms of action

Australian Prescriber

Volumn 39, Issue 5, 2016, Pages 164-167

  Page, Michael M ^a   Watts, Gerald F ^b  

^a FIONA STANLEY HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Familial hypercholesterolaemia; LDL cholesterol; Proprotein convertase subtilisin kexin type 9

Indexed keywords

ALIROCUMAB; EVOLOCUMAB; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASE 9 INHIBITOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CARDIOVASCULAR RISK; DRUG ACTIVITY; ENZYMATIC DEGRADATION; ENZYME BINDING; ENZYME INHIBITION; FAMILIAL DISEASE; GENE; GENE MUTATION; HUMAN; HYPERCHOLESTEROLEMIA; LIVER CELL; META ANALYSIS (TOPIC); NONHUMAN; PCSK9 GENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC);

EID: 85017484987     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2016.060     Document Type: Article

References (15)

1. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47. http://dx.doi.org/10.1126/science.3513311
2. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 2003;100:928-33. http://dx.doi.org/10.1073/pnas.0335507100
3. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-6. http://dx.doi.org/10.1038/ng1161
4. Cohen JC, Boerwinkle E, Mosley TH Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-72. http://dx.doi.org/10.1056/NEJMoa054013
5. Page MM, Stefanutti C, Sniderman A, Watts GF. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9. Clin Sci (Lond) 2015;129:63-79. http://dx.doi.org/10.1042/CS20140755
6. Leren TP. Sorting an LDL receptor with bound PCSK9 to intracellular degradation. Atherosclerosis 2014;237:76-81. http://dx.doi.org/10.1016/j.atherosclerosis.2014.08.038
7. Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, et al. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation 2013;127:2403-13. http://dx.doi.org/10.1161/CIRCULATIONAHA.113.001592
8. Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol 2012;32:1585-95. http://dx.doi.org/10.1161/ATVBAHA.112.250043
9. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013;128:2113-20. http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004678
10. Chan JC, Piper DE, Cao Q, Liu D, King C, Wang W, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 2009;106:9820-5. http://dx.doi.org/10.1073/pnas.0903849106
11. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al.; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489-99. http://dx.doi.org/10.1056/NEJMoa1501031
12. Ballantyne CM, Neutel J, Cropp A, Duggan W, Wang E, Plowchalk D, et al. Efficacy and safety of bococizumab (RN316/PF-04950615), a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 in statin-treated hypercholesterolemic subjects: results from a randomized, placebo-controlled, dose-ranging study (NCT: 01592240). J Am Coll Cardiol 2014;63 Suppl:A1374. http://dx.doi.org/10.1016/S0735-1097(14)61374-7
13. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 2014;63:1278-88. http://dx.doi.org/10.1016/j.jacc.2014.01.006
14. Koschinsky M, Boffa M. Lipoprotein(a) as a therapeutic target in cardiovascular disease. Expert Opin Ther Targets 2014;18:747-57. http://dx.doi.org/10.1517/14728222.2014.920326
15. Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem 2015;290:11649-62. http://dx.doi.org/10.1074/jbc.M114.611988